The biology of atypical hemolytic uremic syndrome has been shown to involve inability to limit activation of the alternative complement pathway, with subsequent damage to systemic endothelial beds and the vasculature, resulting in the prototypic findings of a thrombotic microangiopathy. Central to this process is the formation of the terminal membrane attack complex C5b-9. Recently, application of a monoclonal antibody that specifically binds to C5, eculizumab, became available to treat patients with atypical hemolytic uremic syndrome, replacing plasma exchange or infusion as primary therapy. This review focuses on the evidence, based on published clinical trials, case series, and case reports, on the efficacy and safety of this approach.
Introduction
This article is designed to provide a critical appraisal of the efficacy and safety of eculizumab in atypical hemolytic uremic syndrome (aHUS) in children and adults. We analyze published work based on the level of evidence from controlled trials through anecdotal case series and individual case reports. A MEDLINE search was performed to identify all relevant articles using the terms "atypical hemolytic uremic syndrome or aHUS" and "eculizumab." We will review why it has become the treatment of choice for aHUS, and current limitations in the data.
Clinically, thrombotic microangiopathy (TMA) can occur in a number of diseases. However, the most commonly associated diseases are hemolytic uremic syndrome (HUS, either shiga-toxin-associated or aHUS), thrombotic thrombocytopenic purpura (TTP), and disseminated intravascular coagulation. HUS is characterized by the triad of microangiopathic hemolytic anemia (MAHA), thrombocytopenia, and moderate to severe acute kidney injury, while TTP is defined by the pentad of MAHA, severe thrombocytopenia, fever, and, commonly, neurological impairment and milder acute kidney injury than in HUS, although such features may occur in HUS as well. Disseminated intravascular coagulation is rather distinct clinically, with the presence of an abnormal coagulation profile predominating, and often associated with sepsis.
aHUS is a prototypic TMA, caused by an inability to stop alternative pathway (AP) complement activation of the terminal membrane attack complex (MAC, C5b-9), thereby leading to damage of endothelial cell beds through the body, as well as the inability to block platelet and white blood cell activation in the circulation, which adds further to the microangiopathic process. 1 There is a clear genetic underpinning documented in nearly two-thirds of aHUS cases, relating to an inactivating mutation in proteins that downregulate AP activity (factor H, factor I, membrane cofactor protein , thrombomodulin), or with an activating mutation in C3 or factor B that renders them constitutively overactive and not subject to modulation of activity, or through the formation of anti-factor H immunoglobulin G (IgG) antibodies (which commonly are associated with gene rearrangements or deletions in complement factor H [CFH]-related protein-1 and -3), all of which lead to AP generation of the MAC.
Additional cases of aHUS may be seen in a variety of circumstances that lead to AP complement overactivity coupled with the absence of sufficient regulation, including systemic lupus erythematosus, scleroderma, malignant hypertension, drugs, [2] [3] [4] and pregnancy, among other conditions. A recent study 5 of 193 patients that employed a high-throughput genetic screening process demonstrated the ability to find most mutations and raised the question of novel genetic variants in the pathogenesis of aHUS as well. The combination of a "predisposing factor" (genetic mutations/variants) with a "precipitating factor" (infection, drug, systemic disease, and others) may overcome the ability to control AP and, therefore, leads to the onset of aHUS. In a recent paper, Jodele et al 6 evaluated candidates for bone marrow transplant regarding genetic susceptibility to TMA and found that gene variants in complement regulators were more common among patients with transplant-associated TMA.
Common to aHUS, regardless of the cause, is the activation of the MAC, which starts with hydrolysis of complement factor C5 into C5a and C5b. The humanized monoclonal antibody, eculizumab, binds to the complement protein C5 with high affinity and inhibits its cleavage to C5a and C5b, thereby preventing the subsequent generation of the MAC. Eculizumab contains the murine complementaritydetermining regions of the m5G1.1 monoclonal antibody, which were grafted onto the human framework light-and heavy-chain variable regions. The use of the germ line framework acceptor sequences was employed to minimize the potential for immunogenicity. The heavy-chain constant region of the parent antibody was replaced by components of both human IgG 2 and IgG 4 and, therefore, lacks the ability to activate complement and to bind Fc receptors. Such modifications should minimize the potential of eculizumab to induce pro-inflammatory responses. 7, 8 Eculizumab was approved in 2011 in the United States 9 and shortly thereafter in Europe. 10 Currently, the drug has been used worldwide for the treatment of aHUS. A recent consensus document 11 almost uniformly recommended that, once the diagnosis of aHUS is made, eculizumab should be started immediately thereafter.
Reliable tools to monitor the response to eculizumab, outside of reversal of the clinical features of aHUS, are yet to be defined. In patients with paroxysmal nocturnal hemoglobinuria (PNH), a complement-mediated disease for which eculizumab was first approved, there seems to be a correlation between activity of 50% hemolytic complement (CH50) assay ,10% and free eculizumab levels .50 µg/mL with efficacy of the drug in reducing hemolysis. 12 Although the use of CH50 is feasible in daily practice, there is no prospective data in patients with aHUS to confirm its usefulness, and a standard value to correlate with complement blockade is missing. In the National Health Service (NHS) Commissioning Policy on aHUS in England report, 13 monitoring was done by both CH50 and AP (AP50) hemolytic assay, where complete absence of hemolytic activity was used as criteria for adequate complement blockade. Based on these criteria, only two out of 43 patients treated needed increased dosing of eculizumab (one child and one adult post-transplant). Jodele et al 14 reported on the use of eculizumab to treat six children with severe hematopoietic stem cell transplant-TMA and adjusted the dose for a therapeutic level .99 µg/mL with resolution in four of six children. In this study, CH50 was used to monitor the level of complement blockade (CH50 level #4 complement activity enzyme units used in this series), and the authors found that children needed higher doses or smaller intervals of eculizumab infusions compared with the US FDA-approved regimen for children with aHUS. Two patients died despite dose intensification, but were critically ill. 14 To assess the response to eculizumab in a different manner, and using retrospective data, Noris et al 15 documented a different biomarker of C5 blockade in patients with aHUS, using an ex vivo test that employed vascular endothelial cells that predicted clinical effectiveness of eculizumab in vivo and might guide drug dosing and/or timing. In this study, the authors demonstrated that aHUS patients with or without identified complement gene mutations or anti-CFH antibodies consistently and chronically activate complement on endothelium. Using an in vitro system with adenosine diphosphate-activated endothelial cell culture, blood samples from patients diagnosed clinically with aHUS, with or without overt TMA, induced more C3 and C5b-9 deposition than control sera, documenting the higher sensitivity (100%) of this ex vivo assay vs elevated plasma soluble (s)C5b-9 levels in detecting complement dysregulation in aHUS. In contrast, this did not happen in patients with C3 glomerulopathy in which the AP is dysregulated in the fluid phase, reinforcing the concept of an endothelial-restricted complement deposition in aHUS. C5b-9 deposits were prevented by the anti-C5 antibody eculizumab. More work remains to understand what biomarker of disease activity and efficacy of eculizumab therapy might be appropriate. aHUS-associated mutant proteins may often effectively regulate complement in the fluid (blood) phase, which would explain the normal or near-normal circulating C3 levels in many mutation carriers. Gain-of-function mutations of CFB and C3 form a C3 convertase resistant to decay by endothelial cell/membrane-bound regulators. Such findings provide strong evidence that aHUS is a disease of unrestricted endothelial complement activation.
Treatment of aHUS in the pre-eculizumab era
Following the landmark paper published by Bell et al in 1991, 16 plasma exchange/plasma infusion (PE/PI) became the initial treatment for most patients with aHUS. Initial reports [17] [18] [19] presented variable outcomes of patients with HUS in case series or reports in which laboratory assessments for differential diagnosis between shigatoxin HUS, aHUS, or TTP were not available. More recently, Noris et al, 20 in an analysis of 273 patients with either sporadic (n=191) or familial (n=82) aHUS and treated with PE/PI, found that twothirds of adult patients had a bad outcome (dialysis or death) in a 3-year follow-up, which varied according to genotype. They reported a mortality rate of 8% and 11%, after first manifestation and 3 years of follow-up, respectively. Despite case reports of "good" outcomes with plasma therapy (three and five patients, respectively), 21, 22 in a recent report from the French group (n=214 patients), the mortality rate was higher in children than adults (8% vs 2%) after 4 years of followup, with fatal outcomes, despite initial plasma therapy. 23, 24 Cataland et al, 25 in a retrospective registry analysis of 19 patients diagnosed with aHUS, found that only six of the 16 patients treated with PE/PI had a complete hematologic and kidney recovery (and in contrast to seven of the nine patients treated with eculizumab). Although the genotypephenotype correlation data indicate that MCP mutations are associated with a better prognosis than CFH mutations, this is not always straightforward, since there are patients who present severe and life-threatening manifestations with different degrees of response to plasma therapy independently of having an identifiable mutation or not. 22, 26, 27 Among the potential risk factors for apheresis-related complications in low-weight patients, such as children and small adults, are those related to the relatively large extracorporeal volume and the difficulties related to ensuring adequate vascular access. There is an almost 50% incidence of any adverse event including hypotension, symptomatic hypocalcemia, allergic reactions, and catheter-related thrombosis, and 1% death rate, in patients undergoing plasmaexchange therapies. 28 De et al 29 published a review of 28 pediatric cases of aHUS with identified mutations who were treated with supportive measures, PE/PI, kidney transplant (±PE/PI), or liver/ combined liver-kidney transplantation in the pre-eculizumab era. Overall, 13 of the 28 patients either died or had a relapse, and 15 recovered and were well until last follow-up (the latter included five patients with MCP mutations). Among the 20 patients with CFH mutations (homozygous or compound heterozygotes), ten either died or relapsed and ten recovered. Three patients with anti-factor H antibodies had poor outcomes (one needed dialysis and two had multiple relapses). The authors concluded that, despite major progress in the understanding of the underlying pathogenetic mechanisms, aHUS remains a severe childhood disease with potential adverse outcomes, including the development of end-stage renal disease (ESRD), disease recurrence after transplantation, and death.
Analysis of the published data for eculizumab in aHUS
Prospective controlled trials of eculizumab in patients with aHUS
In 2013, Legendre et al published the results of the first prospective trials of eculizumab in aHUS conducted in Europe and North America with patients 12 years of age or older. 30 These trials had followed upon dozens of anecdotal reports of the use of eculizumab for the treatment of aHUS, which we review later in this article.
Patients were enrolled in two prospective trials according to levels of kidney and hematologic abnormalities:
Trial 1 ("progressive TMA"): kidney impairment (creatinine $ upper limit of normal [ULN]) and persistent thrombocytopenia (,150×10 9 /L) with evidence of hemolysis (low haptoglobin, presence of schistocytes, or lactate dehydrogenase [LDH] $ ULN) despite four or more sessions of plasma therapy (PE/PI).
Trial 2 ("longstanding TMA"): kidney impairment (creatinine $ ULN) with evidence of hemolysis (low haptoglobin, presence of schistocytes, or LDH $ ULN) and no platelet count decrease .25% during 8 consecutive weeks during plasma therapy.
Among other inclusion criteria were a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) activity .5%, and shigatoxin negative in stools during enrollment screening. Gene mutations or anti-factor H antibodies were not a prerequisite.
While end points were different for each trial (Table 1   30,31 ), common safety issues were assessed. Both groups received eculizumab for 26 weeks according to a previously predetermined dosing schedule 9 and were allowed to continue in an extension-phase study, with the 2-year follow-up results published recently by Licht et al. 31 In the "progressive TMA trial," the primary end point was to hinder "complement-mediated TMA," defined by a composite measure (Table 1) . At the beginning of the trial, 17 patients (one adolescent) were enrolled, and the median interval between diagnosis of aHUS and screening was 9.7 months. Time from onset of the then-prevalent manifestation of TMA to screening was 0.8 months. 31 Except for one patient, all received plasma therapy during the week before eculizumab was started. All patients had an eGFR (estimated glomerular filtration rate) below 60 mL/min/1.73 m 2 for 17 days (median duration), while eleven patients received dialysis either before or at first dose of eculizumab, with a median (interquartile range) duration of 22 days. In this study, seven patients had prior kidney transplants. No mutations or factor-H antibodies were found in 24% of patients. Patients received eculizumab ranging from 2 weeks to 90 weeks in duration (median 64 weeks on treatment), and 15/17 patients completed 26 weeks of treatment.
Complete TMA response (criteria described in Table 1 ) was reached by 65% and 76% of patients at week 26 and 2 years, respectively. Many additional analyses were performed based on the data in this trial. Half of the patients with thrombocytopenia at baseline had a normal platelet count after 1 week, which remained normal at week 26 in almost 90% of patients. Normalization of platelet count and LDH levels occurred in near 90% of patients, and the great majority of patients enrolled did not receive PE or PI for the entire duration of the study. After eculizumab treatment, kidney function improved progressively with an eGFR increase of 32 mL/min/1.73 m 2 from baseline to week 26. In 80% of patients, dialysis was discontinued, and they remained dialysis-free through the treatment period (26 weeks).
Among the 15 patients with aHUS who completed 26 weeks of eculizumab, 13 were enrolled in the extension phase. 31 At the 2-year time point, eleven of 13 patients remained on eculizumab (two had withdrawn because of decrease in kidney function). Platelet count was normalized in nearly 90% at the 1-year and 2-year cutoffs (two patients were withdrawn from the study before 26 weeks of treatment because of lack of improvement). Improvements in eGFR were maintained after the first year of this trial. eGFR increased from 33 mL/min/1.73 m 2 to 37 mL/min/1.73 m 2 between week 26 and the 2-year cutoff, with an absolute mean (SD) eGFR of 56 (40) mL/min/1.73 m 2 at 26 weeks, and 56 (30) mL/min/1.73 m 2 at the 2-year data analysis. Four of the five patients (80%) were able to stop dialysis (one before the first dose of eculizumab and three at a mean of 1 week after the starting on eculizumab). One patient needed to start dialysis during the 26-week study period (this patient discontinued the study and was not included in the 2-year analysis). Another patient started dialysis on study day 444, and also discontinued. In summary, two patients were on dialysis at the 2-year cutoff. 31 There was the same number of transplanted patients, and none lost their graft.
In the second controlled trial, comprising "patients with longstanding TMA," 30 patients were eligible for study entry if they had kidney impairment, stabilization in platelet count for at least 8 weeks before the first dose of eculizumab, and received plasma therapy at least once every 2 weeks (but no more than three times per week). The primary end point (Table 1) for this trial was "TMA event-free status" for at least 12 weeks in duration. The interval between diagnosis and screening was longer (median, 48.3 months) than seen 
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in the progressive TMA trial discussed. 30 In the longstanding TMA trial, 35% of the participants had no identified mutation in AP complement or the presence of anti-factor H antibodies. The majority of patients had chronic renal disease (eGFR below 60 mL/min/1.73 m 2 for a median of 75 months before treatment with eculizumab; two patients on dialysis), and with the majority of patients being treated with plasma therapy for 10 months (median). Time from onset of the clinical manifestation of aHUS to screening was 8.6 months (median), and all patients received PE/PI before eculizumab. The median (range) duration of dialysis during the current manifestation was 1.7 (0.32-3) years. Eight patients had a prior kidney transplant. 31 In this "longstanding TMA" trial, complete TMA response (criteria detailed in Table 1 ) increased from 25% at 26 weeks, to 55% at the 2-year cutoff. Treatment with eculizumab varied in length from 26 weeks to 74 weeks (median 62 weeks). By week 26, 80% of the patients met the primary study end point noted above; four patients did not achieve the proposed end point because of variations in platelet count, although levels were within normal limits. All patients stopped plasma therapy, and none started new dialysis.
After starting eculizumab, eGFR increased from 6 mL/ min/1.73 m 2 to 9 mL/min/1.73 m 2 between baseline and week 60; the absolute mean (SD) eGFR also increased from 37 (21) mL/min/1.73 m 2 to 40 (18) mL/min/1.73 m 2 at the 2-year time point. Thereafter, initial eGFR improvements were maintained during the 2-year eculizumab treatment. Two patients required dialysis at baseline: one was on dialysis at the 2-year analysis, and the other received hemodialysis until renal transplantation (on day 217). During the 2 years of the study, one patient started dialysis (days 695-696) during admission for an intestinal hemorrhage and died of that complication. There were no new kidney transplants or graft losses.
Of the 20 patients (five adolescents) who completed the initial 26-week study, 19 entered the extension period, with eculizumab continued up to 78 weeks. Eighteen patients remained on treatment with eculizumab until the data analysis at 2 years. 31 The median (range) duration of eculizumab exposure in this trial was 0.31 (0.07-0.35) years.
Both in the "Progressing TMA trial" and in the "Longstanding TMA trial," earlier initiation of eculizumab (time between the current manifestation and enrollment) was associated with a greater improvement in the eGFR. Eculizumab responses in the primary end points were seen in patients regardless of identified genetic mutations or CFH autoantibodies, both in the initial and extension phases. 30, 31 In both trials, a significant improvement in health-related quality of life (QOL) was seen with eculizumab treatment. 30 Quality of life started improving after 1 week in the first trial and 3 weeks in the second trial, and was maintained over the 2 years of treatment. 31 The dosing of eculizumab was designed to achieve a minimum blood concentration of 50-100 µg/mL to ensure complete complement blockade and to provide sustained low levels of free C5 and high levels of C5 cleavage suppression. 30 A biomarker of terminal complement activity remained inhibited over 2 years in both studies, 31 as measured by a modified CH50 assay (method not described).
Open-label, single-group, multicenter, multinational clinical trial in adult patients
This clinical trial, performed after those discussed 30, 31 and registered at www.clinicaltrials.gov as NCT01194973, 32 was conducted in adult patients with aHUS. This was a 26-week, open-label, nonrandomized, single-group, multicenter trial of eculizumab in patients with aHUS in which patients could continue to receive eculizumab in an extension phase. Adult patients ($18 years of age) with a diagnosis of aHUS were enrolled at 23 centers in North America and Europe. Eligible patients had platelet counts ,150×10 9 /L, hemoglobin levels # the lower limit of the normal range, LDH levels $1.5 times above ULN, serum creatinine levels at or above ULN at screening, ADAMTS13 activity $5%, and no positive shigatoxin-producing Escherichia coli test. An identified complement gene mutation, associated polymorphism, or factor H autoantibody was not required. Patients were categorized according to whether they received PE/PI or not during the pretreatment period, defined as beginning on the start date of the current aHUS manifestation up to the first dose of eculizumab.
Forty-one adult patients with aHUS were treated; 38 (93%) completed the initial 26-week clinical study period and 21 (51%) continued treatment of 1 year during the optional extension period. Twenty patients (49%) had one or multiple identified mutations in complement genes and/or anti-factor H antibody. Thirty patients (73%) were enrolled during their first identified clinical TMA manifestation. At screening, the mean (SD) platelet count was 119.1 (66.1)×10 9 /L, mean haptoglobin was 0.6 (0.4) g/L, and mean LDH level was 492.9 (500.9) U/L. Thirty-five patients (85%) received PE/PI before eculizumab (mean, 9.6 sessions; range, 1-26) during the pretreatment period. Twenty-four patients (59%) were receiving dialysis at , creatinine, sC5b-9, and C5a) were used in this study, from either serum, ethylenediaminetetraacetic acid plasma, or urine samples obtained from patients with aHUS at baseline, before eculizumab treatment, and at weeks 1-3, 4-6, 12-17, 26-33, 38-42, and 49-54 during eculizumab treatment. Levels of plasma and serum markers were evaluated from healthy volunteers and patients with aHUS at baseline and at regular intervals during eculizumab treatment over the course of a 1-year period; markers in urine were evaluated over the course of 26 weeks of eculizumab treatment.
At baseline, all biomarkers were elevated significantly in the majority of patients with aHUS compared to levels measured in adult healthy volunteers; 69%-83% of patients with aHUS also showed significantly elevated levels of candidate renal injury biomarkers (ninefold to 48-fold higher than levels measured in healthy people). Levels of these biological markers were increased in patients who presented hematologic improvement from screening to the first dose of eculizumab, including those patients receiving plasma therapy. 33 Eculizumab treatment reduced terminal complement activation (C5a and sC5b-9) and selected renal injury markers (clusterin, cystatin-C, b2-M, and L-FABP-1) to levels observed in the healthy volunteers. It also significantly reduced inflammation (sTNFR1), coagulation (prothrombin F112 and d-dimer), and endothelial damage (thrombomodulin) biomarkers compared to pretreatment levels (and frequently to levels seen in healthy individuals). Although AP activation and endothelial activation markers decreased, their mean levels were still elevated compared to healthy volunteers. This may reflect persistent complement activation in aHUS, even though terminal complement blockade with eculizumab was achieved. 33 There were no differences in biomarker assessment between patients who were or were not treated with plasma therapy before enrollment. Unfortunately, controls consisting of patients with similar degrees of chronic kidney disease but without aHUS were not studied, so the meaning of the changes must be interpreted cautiously. At present, there is no uniformly agreed-upon biomarker of either disease activity or response to eculizumab.
Anecdotal case reports of use of eculizumab in patients with aHUS Tables 2  34-49 and 3 22,50-78 present the case reports of adult and pediatric patients with aHUS who received eculizumab according to the current label-approved schedule. We were able to find that 39 adults and 38 children were treated in the absence of a clinical trial in the published literature. Overall hematologic and kidney responses to eculizumab, as defined and judged by the authors of the case reports, were 90% and 56% for adults, respectively, and 100% both hematologic and kidney response in children receiving eculizumab. Where applicable, we describe the precipitating factor of ongoing TMA, herein termed the "complement-amplifying condition." The reports in which eculizumab was used for diseases other than aHUS are not mentioned in this review. The reports in which eculizumab was used in a non-FDA-approved dosing schedule are mentioned in Table 4 .
Eculizumab and kidney transplantation
Recent studies have shown that the risk of post-transplant recurrence of aHUS is linked to the underlying genetic abnormality. 79, 80 Higher risks are seen in patients with mutations in circulating complement proteins and regulators genes, in contrast to patients with mutations in MCP (CD-46) who generally, but not always (such as when the MCP mutation is combined with another mutation or highrisk polymorphism), achieve a good kidney transplant outcome. Recurrence of aHUS is shown to have dismal graft survival, 80 and led to the recommendation, therefore, in the pre-eculizumab era, that isolated renal transplantation was contraindicated in aHUS patients. Combined kidney-liver transplantation and prophylactic PE have been used to prevent post-transplant recurrences with variable outcomes. 81 More recently, evidence on the benefits of eculizumab in the prevention and treatment of aHUS recurrence has been demonstrated (Table 4) .
Retrospective, multicenter review of eculizumab use in renal transplant recipients
Zuber et al conducted a retrospective, multicenter study to assess eculizumab for the prevention or treatment of posttransplant manifestations in patients with aHUS. 79, 82 From the 22 patients included in the study, 13 patients were enrolled 48 aHUS was defined by MAHA, thrombocytopenia, and renal failure with plasma ADAMTS13 activity .10%. Other causes of the syndrome of MAHA and thrombocytopenia, such as DIC, systemic autoimmune disorders, lupus anticoagulants, metastatic neoplasms, shigatoxin, or neuraminidase-associated HUS, were excluded Case 1: patient presented with bloody diarrhea negative for shigatoxins Case 2: patient presented 3 months after undergoing autologous HSCT for advanced multiple myeloma Case 3: patient had recurrent episodes of severe hypertension accompanied by mild renal insufficiency and MAHA for 4.5 years before he was found to have aHUS Case 4: patient presented at 22 weeks of her third pregnancy and was initially assumed to have preeclampsia; however, her disease persisted after termination of pregnancy Case 5: patient had kidney biopsy performed for renal failure at 3 weeks after her seventh triweekly course of chemotherapy with gemcitabine and carboplatin for metastatic cholangiocarcinoma 5 After eculizumab infusion, platelet count began to exhibit steady increase within 3 days in each of the 5 courses in cases 1- 
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in Europe 82 and nine were reviewed from the published literature. [83] [84] [85] Cases were reported in two groups: 1) patients who received eculizumab prior to transplantation to prevent subsequent TMA manifestations (n=9); and 2) patients who received eculizumab to treat post-transplant aHUS manifestations (n=13). Individual patient information describing eculizumab use prior to the transplantation is included in Table 4 . 52, 53, 73, 79, 82, [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] Use of eculizumab prior to transplantation (n=9)
Nine patients received eculizumab prior to transplantation to prevent post-transplant aHUS manifestations and allograft loss. Five patients had heterozygous mutations in CFH, three had a large CFH/CFHR1 nonhomologous recombination, and one had a gain-of-function C3 mutation. Three patients had received four kidney transplants, all lost to post-transplant aHUS manifestations. Median age at time of present transplant was 9 years (range, 6.4-41.0 years). Two patients had preformed donor-specific antibodies with low titer (mean fluorescence intensity ,1,000) at the time of transplantation. Strategy around the use of eculizumab consisted of one of the following three methods: 1) PE started just before transplantation, then switched to eculizumab after transplantation (n=2); 2) eculizumab initiated 1 week or more before transplantation (n=2); and 3) eculizumab initiated #24 hours before transplantation with additional dose immediately before (n=1) or within 24 hours after (n=4) transplantation. Eight of nine patients treated with eculizumab maintained allograft function and experienced no additional post-transplant aHUS manifestations from 2-39 months of follow-up (mean 14.5 months). One allograft (case #8, Zuber et al 82 ) was lost to immediate arterial thrombosis, despite undetectable CH50 activity. This patient was ultimately successfully retransplanted under peritransplant eculizumab therapy. 11 No significant infectious complications were reported.
Post-transplant treatment of aHUS with eculizumab (n=13)
From the 13 patients who received eculizumab to treat posttransplant aHUS, two received it because of intolerance to plasma therapy or convenience. Ten patients presented with plasma-resistant aHUS. One was treated with complement 37 19 patients who had received four or more weekly 900 mg infusions of eculizumab were identified through a query sent to all nephrology centers in France aHUS was defined as three or more of the following: acute kidney injury (serum creatinine .1.4 mg/dL [120 µmol/L]), mechanical hemolytic anemia, thrombocytopenia, and the presence of TMA features in a kidney biopsy specimen For first-line therapy, 16 patients underwent plasma exchange and 3 patients received eculizumab 19 Median time between aHUS onset and eculizumab therapy initiation was 6 days (range, 1-60 days), and median time to platelet count normalization after eculizumab therapy initiation was 6 days (range, 2-42 days 52 Boy with first manifestation of aHUS at age 2 months and a relapse at age 10 months leading to ESRD despite PI. Remained hypertensive in dialysis and had convulsions at age 5.5 years, when stenosis of left carotid artery and bilateral middle cerebral arteries was diagnosed 1
At age 6.5 years received a kidney transplant under prophylactic eculizumab with no signs of posttransplant aHUS; evolved with seizures and cerebral ischemia on the fourth postoperative day, leading to death Sharma et al (2015) 75 Girl aged 28 days presented with plasma-resistant aHUS with gross hematuria and hypertension 1 After 1 dose of eculizumab, dialysis was discontinued and her hematologic parameters improved; after 11 months of follow-up, she remains on eculizumab and penicillin without recurrence of aHUS or any infectious complications Besbas et al (2013) 55 Newborn aged 5 days with aHUS and full renal and hematologic remission after PI. The patient was discharged with FFP infusions but subsequently developed 3 life-threatening disease recurrences at 1 month, 3 months, and 6 months of age. The last relapse presented with uncontrolled hypertension and impaired renal function while the patient was receiving FFP infusions 1
Five days following the first dose of eculizumab, renal and hematologic parameters returned to normal range and blood pressure normalized; FFP infusions were gradually decreased and stopped; at the time of the report, the patient was 20 months of age and currently on eculizumab treatment every other week with completely normal renal and hematologic parameters 22 Retrospective analysis of 15 children diagnosed with aHUS, which was defined as HUS negative for STEC Three patients had relapses, and 7 had a new diagnosis. Nine children had oliguria or anuria, and 8 required dialysis. Hypertension was observed in 6 patients. Neurologic involvement developed in 6 patients.
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Ten were resistant to, or dependent on, plasma therapy and treated with eculizumab; following the start of eculizumab treatment, all patients achieved full recovery of renal function and hematologic parameters.
Gruppo and Rother (2009) 63 Congenital aHUS: first manifestation at 8 days of life treated with PI; relapses at 3 months, 9 months, and 11 months of age; all treated with PI with good response after 2 weeks; fourth relapse at 18 months unresponsive to PE. blockade as first-line treatment. No mutations were found in two of the 12 patients screened. Overall, there were 17 renal transplants, and 14 had been lost by aHUS recurrence, two by vascular thrombosis, and one by chronic allograft nephropathy. The median interval between renal transplantation and recurrence was 2 months (from 3 days to 5 years). The delay between recurrence and treatment with eculizumab was 30 days (from 1 day to 14 months). Donor-specific antibodies were not detected in any patient, and histological findings of TMA were present on biopsy in 77% of patients (of which one only exhibited signs of antibody-mediated rejection). All but three patients were maintained on eculizumab until last follow-up. Two patients who received a single dose of eculizumab presented a relapse after aHUS remission, but this did not resolve with eculizumab reintroduction; the patients progressed to ESRD. In all patients, there was good hematologic response (defined by the authors), as well as kidney function improvement. In the patients unresponsive to plasma therapy, renal function recovery was inversely proportional to the delay in starting eculizumab therapy, as few patients had kidney function benefit when the drug was started after 1 month. Two patients presented with a pulmonary infection by M. tuberculosis and H. influenza, respectively, and one patient had hypogammaglobulinemia (history of prior splenectomy and use of rituximab), but good outcome with antibiotics and subcutaneous immunoglobulin.
Retrospective single center case series of eculizumab use in renal transplant recipients
Matar et al 90 reported a retrospective study of 12 consecutive patients with an established diagnosis of aHUS who underwent at least one kidney transplant at a single institution between 2003 and 2013. Diagnosis of primary aHUS was confirmed by evidence of thrombocytopenia, hemolytic anemia, acute renal failure, normal ADAMTS13 levels, and negative for shigatoxin-producing E. coli-HUS.
Six patients had an established diagnosis of aHUS as their primary disease prior to their first transplant, three patients were diagnosed with aHUS post-transplant, two patients had an unclear diagnosis as the cause of the primary disease, and one patient was diagnosed with focal segmental glomerular sclerosis as their primary disease. All patients had genetic testing for complement mutations: six patients (50%) had identified complement mutations, including four with CFH mutations, one with an MCP mutation, and one with a THBD mutation. The 12 patients received a total of 23 kidney transplants. Six patients had only a single transplant, three patients had two transplants each, and three patients had more than two transplants. Four patients considered at high risk of post-transplant TMA complications received eculizumab starting 24 hours prior to transplantation. Individual patient information is included in Table 5 . All patients maintained allograft function, and there were no reported TMA complications with 21-34 months of follow-up.
Retrospective, multicenter review of eculizumab use for aHUS in England
Sheerin et al 13 reported on the use of eculizumab commissioned by NHS England in 2013 for both new patients with aHUS and long-duration aHUS, including those who underwent renal transplantation. Overall, 43 patients received eculizumab: 15 (35%) were ,18 years (eleven male, four female); 28 (65%) were adults (nine male, 19 female); 23 (53%) had active progressing TMA, and 20 (47%) had a long duration of aHUS. At the time of publication, 31 (72%) patients were receiving ongoing eculizumab. Three of 14 (21%) patients who discontinued eculizumab had subsequent 
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TMA complications and recommenced therapy with eculizumab (including two patients on dialysis who did not recover renal function but had ongoing hemolysis). At the moment of publication, there were 45 patients (43 adults/two children) on dialysis in England whose primary diagnosis was aHUS. Mutations were identified in 32 (71%) of patients. Of the 13 patients without an identified mutation, five (38%) had lost a previous transplant to recurrent disease. This suggests that in these individuals there is an as-yet unidentified inherited or acquired factor that caused recurrent disease. The majority had not been wait-listed due to risk of subsequent TMA manifestations, and wait listing was made possible with the introduction of the NHS England Commissioning Policy for aHUS.
Use of eculizumab prior to renal transplantation
In the report by Sheerin et al, 13 from April 1, 2013, to March 31, 2014, nine of 45 (20%) aHUS patients received a renal transplant with eight (89%) receiving eculizumab prior to transplantation. One patient received eculizumab for subsequent TMA in the early postoperative period, and all of these renal transplant recipients had good transplant outcomes and continue to receive eculizumab.
Treatment of prevalent patients not on dialysis
Of the eleven patients with long-duration aHUS who were not on dialysis, eight received eculizumab to prevent further relapses. One of these was a patient with a known CD46 mutation who had recurrent episodes of pancreatitis that did not respond to eculizumab, which was withdrawn. Three were transplant patients-one started eculizumab 29 months after transplant when a biopsy undertaken for progressive decline in transplant function showed evidence of a chronic TMA with graft function improvement after eculizumab; two other transplant patients (deemed to have typical HUS) developed a TMA in the graft early after transplantation leading to a revised primary renal diagnosis of aHUS, both of whom had good outcome with eculizumab treatment.
Case reports of kidney transplant patients with aHUS treated with eculizumab
Cases describing use of eculizumab in patients with aHUS prior to transplant and long-term use after kidney transplantation to prevent TMA and therefore the risk of allograft loss are summarized in Table 5 . 11, 40, 82, 83, 90, 97, [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] Of the 26 cases backed with adequate follow-up information, 24 patients (92%) remained free of TMA complications with stable graft function at last follow-up (range, 3 days to 39 months). We refer you to the full publications for complete details.
Limited patient-level information was available in the case series presented by Sheerin et al; 13 therefore, these are not presented in Table 5 .
Safety
Terminal complement activity (MAC) is required for protection from invasive meningococcal disease, and use of eculizumab would heighten the exposure of patients to this risk. Immunization is required by regulatory authorities for the use of eculizumab, and antimicrobial prophylaxis is suggested in the early days after such immunization (on label). In the prospective trials, 30 meningococcal infection, infection-related serious adverse events, and deaths were not reported, and this continued throughout the extension study. 31 In trial 1 ("progressive TMA"), serious adverse events were reported in all patients, one of which was considered severe (hypertension in a chronically hypertensive patient). In trial 2 ("longstanding TMA"), half of the patients had serious adverse events. All serious adverse events related to eculizumab had resolution without interruption of the drug. Beyond the 26th week of treatment, no new adverse events were reported and were similar among different subgroups, including transplant recipients. It is noteworthy that adverse events were reported to diminish over time from week 26 to the 2-year cutoff, and no new or cumulative adverse events were noted. 31 In the series published by Sheerin et al 13 regarding the NHS England Commissioning Policy for aHUS, there were no meningococcal infections described in 43 patients treated with eculizumab and vaccinated according to local guidelines.
The presence of non-neutralizing human anti-human antibodies was confirmed in one patient in trial 1 who received a single dose of eculizumab and discontinued following diagnosis of systemic lupus erythematosus (an exclusion criterion).
In a 10-year-old boy with aHUS and heterozygous factor H mutation who received eculizumab to avoid recurrence of aHUS in the renal allograft, protective serum bactericidal antibody titers ($1:8) were seen after kidney transplantation under immunosuppressive therapy with mycophenolate mofetil, tacrolimus, steroids, and eculizumab over a 27-month observational period. This case illustrates that a humoral immune response to conjugate meningococcus C vaccination may occur and be maintained despite chronic renal disease, kidney transplantation, immunosuppressive 
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A 24-year-old man with diarrhea found to have acute renal failure with MAHA was diagnosed with aHUS. He was initiated on PE and hemodialysis. On day 6, he was started on eculizumab. His renal function progressively improved. His main complication during eculizumab therapy was hypertension-related posterior reversible encephalopathy syndrome. 110 The complement system plays a vital role in preventing life-threatening infections by ensuring optimal functioning of the host immune system. Its dysregulation has been implicated in causing glomerular, hematologic, and transplant-related disorders. Vellanki and Bargman 111 describe a very rare case of Aspergillus niger peritonitis in an ESRD patient on peritoneal dialysis receiving maintenance eculizumab therapy for aHUS. Given that murine models with the same defect as that induced by eculizumab are vulnerable to invasive aspergillosis, it is suggested that the fungal peritonitis in this patient was the result of the eculizumab therapy.
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The long-term safety and efficacy of eculizumab in the pediatric population remain under review. Cullinan et al 59 presented the case of a child with a hybrid CFH/CFHR3 gene who, having had multiple disease relapses despite optimal treatment with PE, commenced eculizumab therapy in August 2010. She remained relapse-free in follow-up at 52 months, and treatment has been well tolerated. Despite vaccination against meningococcal disease and appropriate antibiotic prophylaxis, the patient developed meningococcal bacteremia 30 months into treatment. She presented with nonspecific symptoms but recovered without sequelae with appropriate treatment. The authors suggest vaccination, antibiotic prophylaxis, and annual monitoring and follow-up of vaccine responses. 59 A recently published case series in a pediatric population 112 described a possible relationship of liver injury with the use of eculizumab in eleven children treated with this drug for aHUS in a single center. Elevated liver enzymes were reported in seven children (ages 6-11 years) after starting eculizumab infusions to treat aHUS. Liver enzyme thresholds for drug-induced liver injury (international patterns) were exceeded in five cases, all of which were classified as mixed hepatocellular/cholestatic. Other causes for liver injury such as infections were excluded. One patient developed tender hepatomegaly and a 20-fold liver enzyme elevation after starting eculizumab. Recurrent liver injury following resumption of treatment with eculizumab led to its discontinuation and conversion to plasma therapy. Thus, hepatotoxicity in patients treated with eculizumab for aHUS should be monitored. Despite this clinical finding, further research is necessary to characterize the mechanism of potential hepatotoxicity and also to identify patients at risk. 112 Eculizumab has been used in pregnant women successfully, albeit with PNH 113 and not aHUS. Recently, a case report of safe use of eculizumab in a 26-week pregnant woman with aHUS was described. 38 
Dose modification or eculizumab discontinuation
In the prospective trials, 31 the six patients in trial 1 ("progressive TMA") and two patients in trial 2 ("longstanding TMA") discontinued treatment with eculizumab, with no overt TMA reported up to 8 weeks after withdrawal.
In a separate cohort, Cugno et al 114 used a complement activity assay (Wieslab) to measure alternative lectin-mannose and classical pathways in patients receiving eculizumab. Complement activity was completely suppressed at 1 week, 2 weeks, and 3 weeks after the last eculizumab infusion but only partially suppressed after 4 weeks.
The largest case series of eculizumab discontinuation was provided by Ardissino et al 115 and Carr and Cataland, 116 who published the outcome of eculizumab discontinuation in ten patients aiming at minimizing adverse reactions, including meningitis risk and infusion discomfort, and reducing costs. Patient monitoring was home-based and consisted of urine dipstick testing for blood. During the 95 months of observation, one-third of the patients experienced a relapse (median within 1.5 months), but recovery after eculizumab was restarted. More recently, Ardissino et al 117 published the results of longer follow-up period after discontinuation, and a report of six additional cases. Patients had received eculizumab for a median of 4.3 months (range, 0.5-14.4 months). Eight patients were able to discontinue dialysis therapy, whereas the other eight had never been dialyzed. During a cumulative time off treatment of 243 months, five patients experienced relapse, identified by means of regular home urine dipstick testing, within 6 months of the last eculizumab dose (an average of one relapse per 49 months off therapy). In these patients, eculizumab therapy was restarted, followed by rapid improvement in serum creatinine levels and proteinuria to or below baseline values, and maintained every 3 weeks or 4 weeks based on global complement activity. Eleven patients remained in remission with no signs of acute disease.
The authors concluded that, in aHUS, it is possible and relatively safe to discontinue eculizumab therapy. They discourage discontinuation of eculizumab therapy in kidney transplant recipients with CFH mutations and patients with glomerular filtration rates below 20 mL/min/1.73 m 2 . In patients with anti-CFH antibodies, one should consider discontinuation of eculizumab therapy when the antibody titer is ,2.5 times ULN. Regular home urine dipstick monitoring is suggested for early identification of relapses, especially during acute illnesses and when patients feel unwell.
After the publication of this case series, Wetzels and van de Kar 118 added data for eculizumab treatment discontinuation in patients with aHUS and a CFH mutation. In their report, the authors treated four such patients who were plasma-resistant or -dependent and received eculizumab in accordance with FDA-proposed schedules. By local protocol, treatment is discontinued after 4-6 months if disease activity has disappeared and kidney function has improved and stabilized for at least 4-6 weeks. Eculizumab treatment was withdrawn in three of four patients, two of whom had no signs of disease activity as of their respective 11-month and 17-month follow-ups. Recurrent disease developed in one patient 3 months after eculizumab therapy discontinuation. When they compared these patients with those of Ardissino et al, 117 they noted a difference in the location of the CFH mutations, suggesting that patients with a mutation in exons 19 or 20 may be more prone to recurrence.
There are reports of temporary use of eculizumab in drug-induced TMA. Faguer et al 3 published on use of seven doses of eculizumab starting 30 days after mitomycin C-induced TMA with reversal and no relapse after 1 year of follow-up. At the same time, Gilbert et al 2 published the case of a 2-year-old patient with TMA after cisplatin therapy for neuroblastoma for whom eculizumab was administered for 2 months-there was a relapse 2 months after stopping eculizumab, and the patient was found to have a pathogenic variant in CD46, resuming treatment with complement blockade with good outcome.
Case reports of discontinuation of eculizumab in patients with aHUS are summarized in Table 5 .
Failure of response to eculizumab: possible underlying mechanisms
When patients fail to respond to eculizumab or have frequent episodes of overt hemolysis during treatment, it is important to address the underlying mechanism of resistance, especially associated conditions that enhance complement responses such as infections, drugs, chemotherapy, or surgery, among others.
Mechanisms of TMA not primarily related to complement defects have been described in poor responders to eculizumab, such as methylmalonic aciduria and homocystinuria type C protein mutations with elevated homocysteine levels, which may occur even in adult-onset aHUS 119 and in a case of monoclonal proteinuria. 120 Although the underlying mechanism is still unknown, Schalk et al 74 described a 3-year-old boy with aHUS due to a novel heterozygous truncating complement Factor H mutation in combination with other changes known to be associated with an increased risk for aHUS. Despite eculizumab treatment and maximal suppression of the classical and alternative complement pathways, C3d and sC5b-9 remained consistently elevated and were confirmed by augmented serum-induced endothelial C5b-9 deposits. The patient showed repeated relapses, reflected in ongoing activation in vivo, despite the full inhibition of global AP activity (CH50, APH50) in vitro. The authors state that no laboratory-confirmed parameter definitively reflects the situation on endothelial cells, where microangiopathy is localized. Nevertheless, the initial diagnosis of nonresponse was made on the basis of persistently low C3 (which is commonly seen after treatment), as well as other parameters not acceptably reliable. Insufficient data are given to judge whether relapses were indeed relapses or not.
In a cohort of 345 Japanese patients with PNH who received eculizumab, eleven patients had a poor response. All of them had a single missense C5 heterozygous mutation, whose prevalence among the patients with PNH (3.2%) was similar to that among healthy Japanese persons (3.5%), and which was also identified in the Han Chinese population. A patient of Asian ancestry in Argentina who had a poor response had a very similar mutation. Both C5 (with and without the mutation) caused hemolysis in vitro, but only C5 without the mutation was able to bind to and have its hydrolysis prevented by eculizumab. 121 To date, similar mutations in C5 have not been described in patients with aHUS.
Summary and conclusion
The molecular understanding of the mechanism of TMA related to aHUS has led to the novel therapeutic application of a C5 inhibitor, eculizumab. Controlled clinical trials, following upon dozens of case reports and a few case series, confirm that aHUS may be controlled in the overwhelming majority of patients and likely at a higher frequency than with PE alone by historical database comparisons. Recent consensus guidelines and our extensive review support that
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Despite the impressive clinical outcomes using eculizumab in a variety of circumstances in patients with aHUS that were summarized in our review, there remain absent biomarkers of disease diagnosis, ongoing clinical activity, or response to the drug. As with all pharmacologic agents, risks and side effects may occur; however, in aHUS, these are largely outweighed by efficacy.
